Efficacy and Safety of Volixibat, an Ibat Inhibitor, in Patients with Primary Sclerosing Cholangitis and Moderate-to-Severe Pruritus: Results of the Vistas Trial

Authors

• Cynthia Levy
• Gideon M. Hirschfield
• Mitchell Shiffman
• Muyiwa Awoniyi
• Deepak Joshi
• Debra Weinstein
• Douglas Thorburn
• Alejandra Villamil
• Ynto de Boer
• Parvez Mantry
• Aldo J. Montano-Loza
• Münevver Demir
• Adriaan J. van der Meer
• Lisa Forman
• Jessica Dyson
• Nimer Assy
• Kidist Yimam
• Walid Ayoub
• Thomas Berg
• Marie-Noëlle Hilleret
• Christoph P. Berg
• John Eaton
• Cláudia Couto
• Verena Keitel-Anselmino
• Palak Trivedi
• Eli Zuckerman
• Roger McCorry
• Emily Schonfeld
• Fernando Cairo
• Stuart C. Gordon, Henry Ford HealthFollow

Recommended Citation

Levy C, Hirschfield GM, Shiffman M, Awoniyi M, Joshi D, Weinstein D, Thorburn D, Villamil A, de Boer Y, Mantry P, Montano-Loza AJ, Demir M, van der Meer AJ, Forman L, Dyson J, Assy N, Yimam K, Ayoub W, Berg T, Hilleret M, Berg CP, Eaton J, Couto C, Keitel-Anselmino V, Trivedi P, Zuckerman E, McCorry R, Schonfeld E, Cairo F, Gordon SC. Efficacy and Safety of Volixibat, an Ibat Inhibitor, in Patients with Primary Sclerosing Cholangitis and Moderate-to-Severe Pruritus: Results of the Vistas Trial. J Hepatol 2026; 84:S10-S11.

Document Type

Conference Proceeding

Publication Date

5-1-2026

Publication Title

J Hepatol

Keywords

Gastroenterology & Hepatology

Volume

84

First Page

S10

Last Page

S11